Atopic Dermatitis - Drug Pipeline Landscape, 2023

Atopic Dermatitis - Drug Pipeline Landscape, 2023

Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may crack and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness.

Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger an immune system response that causes the inflamed skin and other symptoms.

Atopic dermatitis (eczema) symptoms include dry, cracked skin, itchiness, rash, bumps, on brown or black skin, oozing and crusting, thickened skin, darkening of the skin around the eyes, raw, sensitive skin from scratching.

Healthcare provider will diagnose eczema examining the skin. However, the following tests may be performed for confirmation, an allergy skin test, blood tests and a skin biopsy to distinguish one type of dermatitis from another.

Treatment of atopic dermatitis starts with moisturizing and self-care habits. These are sometimes combined with other treatments like medications and therapies. Medications including products applied to the skin, anti-infective drugs and anti-inflammatories. Therapies like wet dressings, light therapy and counselling may also help based on the severity.

There are many clinical trials ongoing in atopic dermatitis drug development. Some of the most promising trials are studying new treatments for atopic dermatitis, such as biologic drugs. Biologic drugs are made from living cells and are designed to target specific parts of the immune system. They have the potential to be more effective and have fewer side effects than traditional drugs. Other clinical trials are studying new ways to deliver existing treatments, such as through patches or creams.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Atopic Dermatitis treatment such as ARQ-151, Delgocitinib, FURESTEM-AD, and others. Key players involved in the development of therapies to treat atopic dermatitis are AbbVie, Akesobio Australia Pty Ltd, AstraZeneca, Amgen, AOBiome LLC and others. One drug is under late stage pre-registration, Nine drugs are under Phase III clinical trials and 60+ drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.

In June 2022, The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. A regulatory filing for this age group is under review by the European Medicines Agency and the company is planning for submissions to regulatory authorities in additional countries and the preparations are underway.

Report Highlights

Global Insight Service's, Atopic Dermatitis - Drug Pipeline Landscape, 2023 report provides an overview of the Atopic Dermatitis pipeline drugs. This report covers detailed insights on Atopic Dermatitis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Atopic Dermatitis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.